RESUMEN
Objective To explore the effect of paclitaxel with carboplatin combined chemotherapy on hemocyte re-lated indexes,vascular endothelial growth factor(VEGF)and tumor markers in ovarian cancer(OC)patients.Methods OC patients combined chemotherapy(CC)group and ovarian benign tumor control group with 50 cases in each.The pathological changes in the ovarian cells were observed by HE staining and the expression of VEGF was observed by immunohistochemical staining(IHC).Blood cell was counted by flow cytometry(FC).Serum car-bohydrate antigen 125(CA125)and human epididymal protein 4(HE4)were measured by electrochemical lumi-nescence(ECL).Results Compared with control group,the ovarian tissue structure was disordered and the cell atypia was obvious in OC.VEGF expression was significantly enhanced.Platelet count(PLT),CA125 and HE4 were significantly increased(P＜0.01).However,necrotic cells were observed in ovarian tissue of CC group.VEGF expression was inhibited.PLT count and the level of CA125 and HE4 were significantly lower than those of control group after chemotherapy(P＜0.01).Conclusions Combined chemotherapy may regulate the level of VEGF,CA125 and HE4 in OC patients.
RESUMEN
Objective To evaluate the value of PET/CT in preoperative assessment and postoperative monitoring of ovarian cancer. Methods A retrospective analysis was conducted in 45 patients of ovarian neoplasm with clinical records underwent 18F-FDG PET/CT, including 10 patients underwent PET/CT before surgery and 35 patients after surgery. The clinical follow-up time was 6 months at least. The diagnosis based on pathology and clinical follow-up data. Results (1) The sensitivity, specificity and accuracy of PET/CT in detecting ovarian cancer were 94.6%,75.0%and 91.1%, respectively. (2) Ten patients before surgery were all detected tumor by PET/CT, but 2 of them were false positive based on pathologic results. (3) Two patients with non-standard surgery were detected tumor by PET/CT. In 33 patients after standard surgery, 6 patients were no tumor detected by PET/CT. In addition,4 patients with normal CA125 and no signs of recurrence and metastasis were detected tumor by PET/CT. The pathology and clinical follow-up data supported the results. 23 patients with higher CA125 were diagnosed recurrence and metastasis based on pathology and clinical follow-up data, 21 of them were detected tumor by PET/CT. Conclusion 18F-FDG PET/CT plays an important role in preoperative assessment, early diagnosis and accurate positioning of recurrent and metastasis of ovarian cancer. It can be used to guide the clinical treatment.